Interventions for treating intrahepatic cholestasis in people with sickle cell disease.

BACKGROUND Sickle cell disease is the most common hemoglobinopathy occurring worldwide and sickle cell intrahepatic cholestasis is a complication long recognized in this population. Cholestatic liver diseases are characterized by impaired formation or excretion (or both) of bile from the liver. There is a need to assess the clinical benefits and harms of the interventions used to treat intrahepatic cholestasis in people with sickle cell disease. This is an update of a previously published Cochrane Review. OBJECTIVES To assess the benefits and harms of the interventions for treating intrahepatic cholestasis in people with sickle cell disease. SEARCH METHODS We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched the LILACS database (1982 to 23 May 2017), the WHO International Clinical Trials Registry Platform Search Portal (23 May 2017) and ClinicalTrials.gov.Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 12 April 2017. SELECTION CRITERIA We searched for published or unpublished randomised controlled trials. DATA COLLECTION AND ANALYSIS Each author intended to independently extract data and assess the risk of bias of the trials by standard Cochrane methodologies; however, no trials were included in the review. MAIN RESULTS There were no randomised controlled trials identified. AUTHORS' CONCLUSIONS This updated Cochrane Review did not identify any randomised controlled trials assessing interventions for treating intrahepatic cholestasis in people with sickle cell disease. Randomised controlled trials are needed to establish the optimum treatment for this condition.

[1]  A. Keaveny,et al.  Liver Transplantation for Acute Liver Failure Secondary to Acute Sickle Intrahepatic Cholestasis. , 2020, The American journal of gastroenterology.

[2]  A. Bagga,et al.  Sickle Cell Intrahepatic Cholestasis with Acute Liver Failure and Acute Kidney Injury: Favourable Outcome with Exchange Transfusion , 2019, The Indian Journal of Pediatrics.

[3]  Samy I McFarlane,et al.  Intrahepatic Cholestasis in a Sickle Cell Patient Unresponsive to Exchange Blood Transfusion , 2019, American journal of medical case reports.

[4]  A. Krasinskas,et al.  Orthotropic Liver Transplantation for Acute Intrahepatic Cholestasis in Sickle Cell Disease: Clinical and Histopathologic Features of a Rare Case , 2018, International journal of surgical pathology.

[5]  D. Darbari,et al.  Diverse manifestations of acute sickle cell hepatopathy in pediatric patients with sickle cell disease: A case series , 2018, Pediatric blood & cancer.

[6]  F. Piel,et al.  Sickle Cell Disease. , 2017, The New England journal of medicine.

[7]  J. Makani,et al.  Sickle cell disease in Africa: an overview of the integrated approach to health, research, education and advocacy in Tanzania, 2004–2016 , 2017, British journal of haematology.

[8]  L. C. S. Silva,et al.  Sickle cell intrahepatic cholestasis unresponsive to exchange blood transfusion: a case report , 2017, Revista brasileira de hematologia e hemoterapia.

[9]  J. Jakobsen,et al.  Trial Sequential Analysis in systematic reviews with meta-analysis , 2017, BMC Medical Research Methodology.

[10]  S. Azar,et al.  Sickle Cell Disease: A Brief Update. , 2017, The Medical clinics of North America.

[11]  B. Long,et al.  Emergency Medicine Management of Sickle Cell Disease Complications: An Evidence-Based Update. , 2016, The Journal of emergency medicine.

[12]  A. Malik,et al.  Rare but Lethal Hepatopathy-Sickle Cell Intrahepatic Cholestasis and Management Strategies , 2015, The American journal of case reports.

[13]  J. DePasse,et al.  Acute on chronic liver failure in a patient with sickle cell anaemia (HbSS) , 2015, BMJ Case Reports.

[14]  William J Savage,et al.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. , 2014, JAMA.

[15]  I. Imumorin,et al.  Endothelin-1 but not Endothelial Nitric Oxide Synthase Gene Polymorphism is Associated with Sickle Cell Disease in Africa , 2014, Gene regulation and systems biology.

[16]  Jayda L Erkal,et al.  Endothelium-derived nitric oxide production is increased by ATP released from red blood cells incubated with hydroxyurea. , 2014, Nitric oxide : biology and chemistry.

[17]  S. Thein,et al.  How we treat sickle hepatopathy and liver transplantation in adults. , 2014, Blood.

[18]  C. Morris.  Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy. , 2014, Hematology/oncology clinics of North America.

[19]  D. Gutsaeva,et al.  Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability. , 2014, Blood.

[20]  G. Kato.  No NO means yes to sickle red cell adhesion. , 2014, Blood.

[21]  Jason B. Caboot,et al.  Mini-symposium: Controversies in the Evaluation and Treatment of Sickle Cell Lung Disease Hypoxemia in Sickle Cell Disease: Significance And Management , 2014 .

[22]  M. Mohapatra,et al.  Procalcitonin as a Biomarker of Bacterial Infection in Sickle Cell Vaso-Occlusive Crisis , 2014, Mediterranean journal of hematology and infectious diseases.

[23]  Iain Chalmers,et al.  How to increase value and reduce waste when research priorities are set , 2014, The Lancet.

[24]  R. Yadav,et al.  Endothelial nitric oxide synthase gene polymorphism is associated with sickle cell disease patients in India , 2013, Journal of Human Genetics.

[25]  J. Elion,et al.  Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children , 2013, Haematologica.

[26]  O. Daescu,et al.  The proteomics and interactomics of human erythrocytes , 2013, Experimental biology and medicine.

[27]  K. Sun,et al.  New insights into sickle cell disease: a disease of hypoxia , 2013, Current opinion in hematology.

[28]  R. Ware.  Hydroxycarbamide: clinical aspects. , 2013, Comptes rendus biologies.

[29]  D. Rennie,et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.

[30]  Elie A Akl,et al.  GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. , 2013, Journal of clinical epidemiology.

[31]  M. DeBaun,et al.  Sickle cell disease, vasculopathy, and therapeutics. , 2013, Annual review of medicine.

[32]  David Moher,et al.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.

[33]  David Moher,et al.  Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. , 2012, The Cochrane database of systematic reviews.

[34]  K. Lindor,et al.  Current pharmacotherapy for cholestatic liver disease , 2012, Expert opinion on pharmacotherapy.

[35]  Sharon-Lise T Normand,et al.  Getting the methods right--the foundation of patient-centered outcomes research. , 2012, The New England journal of medicine.

[36]  M. Goldberg,et al.  Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management , 2012, TheScientificWorldJournal.

[37]  Yang Xia,et al.  Adenosine signaling in normal and sickle erythrocytes and beyond. , 2012, Microbes and infection.

[38]  John P. A. Ioannidis,et al.  Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. , 2012, JAMA.

[39]  A. Kaplan.  Complications of Apheresis , 2012, Seminars in dialysis.

[40]  Gordon H Guyatt,et al.  GRADE guidelines: 9. Rating up the quality of evidence. , 2011, Journal of clinical epidemiology.

[41]  Gordon H Guyatt,et al.  GRADE guidelines: 5. Rating the quality of evidence--publication bias. , 2011, Journal of clinical epidemiology.

[42]  G. Guyatt,et al.  GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.

[43]  D. Weatherall.  The inherited disorders of haemoglobin: an increasingly neglected global health burden , 2011, The Indian journal of medical research.

[44]  S. Ballas,et al.  Defining the Phenotypes of Sickle Cell Disease , 2011, Hemoglobin.

[45]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[46]  H. S. Nikhar,et al.  A comprehensive review of diverse issues related to sickle cell disease. , 2011, East African journal of public health.

[47]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[48]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[49]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[50]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[51]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[52]  F. Azzaroli,et al.  The pharmacological management of intrahepatic cholestasis of pregnancy. , 2011, Current clinical pharmacology.

[53]  J. Kerner,et al.  Reversal of Hepatic and Renal Failure from Sickle Cell Intrahepatic Cholestasis , 2011, Digestive Diseases and Sciences.

[54]  D. Covas,et al.  Intrahepatic Cholestasis in Sickle Cell Disease: A Case Report , 2010, Anemia.

[55]  G. Serjeant.  One hundred years of sickle cell disease , 2010, British journal of haematology.

[56]  E. Klings,et al.  Sickle cell anemia and vascular dysfunction: The nitric oxide connection , 2010, Journal of cellular physiology.

[57]  S. Orkin,et al.  Sickle Cell Disease at 100 Years , 2010, Science.

[58]  John P A Ioannidis,et al.  Meta‐research: The art of getting it wrong , 2010, Research synthesis methods.

[59]  E. Ebert,et al.  Gastrointestinal and hepatic complications of sickle cell disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[60]  C. Haywood,et al.  Sickle cell disease in the United States: Looking back and forward at 100 years of progress in management and survival , 2010, American journal of hematology.

[61]  Kristian Thorlund,et al.  Clinical Epidemiology Dovepress , 2022 .

[62]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[63]  Kristian Thorlund,et al.  Estimating required information size by quantifying diversity in random-effects model meta-analyses , 2009, BMC medical research methodology.

[64]  H. Karunatilake,et al.  Exchange transfusion for intrahepatic cholestasis due to sickle beta thalassaemia. , 2009, The Ceylon medical journal.

[65]  L. Benjamin,et al.  Definitions of the phenotypic manifestations of sickle cell disease , 2009, American journal of hematology.

[66]  M. Gladwin,et al.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions , 2009, American journal of hematology.

[67]  Kristian Thorlund,et al.  Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? , 2009, International journal of epidemiology.

[68]  Kristian Thorlund,et al.  Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. , 2009, International journal of epidemiology.

[69]  M. Steinberg.  Genetic Etiologies for Phenotypic Diversity in Sickle Cell Anemia , 2009, TheScientificWorldJournal.

[70]  M. Gladwin,et al.  Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. , 2008, JAMA.

[71]  K. Thorlund,et al.  Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. , 2008, Journal of clinical epidemiology.

[72]  Matthew Darlison,et al.  Global epidemiology of haemoglobin disorders and derived service indicators. , 2008, Bulletin of the World Health Organization.

[73]  P. Muriel,et al.  Beneficial drugs for liver diseases , 2008, Journal of applied toxicology : JAT.

[74]  Cage S. Johnson.  The Liver in Sickle Cell Disease , 2007 .

[75]  M. Creary,et al.  Sickle cell disease: current activities, public health implications, and future directions. , 2007, Journal of women's health.

[76]  T. Pusl,et al.  Intrahepatic cholestasis of pregnancy , 2007, Orphanet journal of rare diseases.

[77]  K. Marsh,et al.  Sickle cell disease in Africa: burden and research priorities , 2007, Annals of tropical medicine and parasitology.

[78]  R. Sarode,et al.  Blood bank issues associated with red cell exchanges in sickle cell disease , 2006, Journal of clinical apheresis.

[79]  Yihong Wang,et al.  Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. , 2006, Journal of the National Medical Association.

[80]  J. Madariaga,et al.  Can exchange transfusions treat postoperative intrahepatic colestasis in patients with sickle cell anemia? , 2006, Transplantation proceedings.

[81]  S. Akbulut,et al.  Chronic liver disease in a patient with sickle cell anemia. , 2006, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[82]  C. Ryan,et al.  Liver transplantation in sickle cell anemia: a case of acute sickle cell intrahepatic cholestasis and a case of sclerosing cholangitis. , 2005, Transplantation.

[83]  Mark T Gladwin,et al.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. , 2005, Blood.

[84]  Chin-Shang Li,et al.  Sickle cell hepatopathy: Clinical presentation, treatment, and outcome in pediatric and adult patients , 2005, Pediatric blood & cancer.

[85]  J. Ioannidis,et al.  Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.

[86]  Iain Chalmers,et al.  Well informed uncertainties about the effects of treatments , 2004, BMJ : British Medical Journal.

[87]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[88]  M. Diringer.  Evidence-based medicine: what do you do when there's no evidence? , 2003, Critical care medicine.

[89]  I. Khurshid,et al.  Sickle cell disease, extreme hyperbilirubinemia, and pericardial tamponade: Case report and review of the literature , 2002, Critical care medicine.

[90]  J. Kench,et al.  Exchange transfusion for severe intrahepatic cholestasis associated with sickle cell disease? , 2002, Journal of clinical gastroenterology.

[91]  C. Danielson.  The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[92]  M. Steinberg.  MODULATION OF FETAL HEMOGLOBIN IN SICKLE CELL ANEMIA , 2001, Hemoglobin.

[93]  T. Therneau,et al.  Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid , 2000, Hepatology.

[94]  S. Thung,et al.  Liver transplantation in a patient with acute liver failure due to sickle cell intrahepatic cholestasis. , 2000, Transplantation.

[95]  P. Alderson,et al.  Should journals publish systematic reviews that find no evidence to guide practice? Examples from injury research , 2000, BMJ : British Medical Journal.

[96]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[97]  C. Gluud.  "Negative trials" are positive! , 1998, Journal of hepatology.

[98]  P. Lane.  Sickle cell disease. , 1996, Pediatric clinics of North America.

[99]  E. Orringer,et al.  Sickle cell intrahepatic cholestasis: approach to a difficult problem. , 1995, The American journal of gastroenterology.

[100]  C. Foster,et al.  Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. , 1995, Gut.

[101]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[102]  N. Freed,et al.  Sickle cell hepatopathy: diagnosis and treatment with exchange transfusion. , 1987, The Journal of the American Osteopathic Association.

[103]  M. Omata,et al.  Pathological spectrum of liver diseases in sickle cell disease , 1986, Digestive Diseases and Sciences.

[104]  M. Omata,et al.  Liver Involvement in Sickle Cell Disease , 1985, Medicine.

[105]  Graham R Serjeant,et al.  Sickle-cell disease , 1984, The Lancet.

[106]  T. Sheehy,et al.  Exchange transfusion for sickle cell intrahepatic cholestasis. , 1980, Archives of internal medicine.

[107]  S. Sánchez-Ramón,et al.  The absence of evidence is not the evidence of absence. , 2016, Human reproduction.

[108]  A. Marti-Carvajal,et al.  Interventions for treating intrahepatic cholestasis in people with sickle cell disease. , 2015, The Cochrane database of systematic reviews.

[109]  Published Online.  Biomedical research: increasing value, reducing waste , 2014 .

[110]  G. Arepally,et al.  Anticoagulation techniques in apheresis: From heparin to citrate and beyond , 2012, Journal of clinical apheresis.

[111]  Gerald Gartlehner,et al.  [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[112]  Gerald Gartlehner,et al.  [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[113]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[114]  S. Mousa,et al.  Diagnosis and management of sickle cell disorders. , 2010, Methods in molecular biology.

[115]  K. Thorlund,et al.  Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. , 2008, Journal of clinical epidemiology.

[116]  C. Morris.  Mechanisms of vasculopathy in sickle cell disease and thalassemia. , 2008, Hematology. American Society of Hematology. Education Program.

[117]  M. Gladwin,et al.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. , 2007, Blood reviews.

[118]  Robert H. Christenson,et al.  The National Academy of Clinical Biochemistry , 2007 .

[119]  P. Swerdlow.  Red cell exchange in sickle cell disease. , 2006, Hematology. American Society of Hematology. Education Program.

[120]  P. Musgrove,et al.  Inherited Disorders of Hemoglobin , 2006 .

[121]  D. Jamison,et al.  Inherited Disorders of Hemoglobin -- Disease Control Priorities in Developing Countries , 2006 .

[122]  K. Hassell,et al.  An evidence-based approach to the treatment of adults with sickle cell disease. , 2005, Hematology. American Society of Hematology. Education Program.

[123]  N. Tiftik,et al.  Long‐term red blood cell exchange can be used to successfully treat sickle cell intrahepatic cholestasis: A case report , 2004, Journal of clinical apheresis.

[124]  Pharmaceutical Development.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE , 1998 .

[125]  D. Goldfinger,et al.  Use of erythrocytapheresis in the treatment of patients with sickle cell anemia , 1984, Journal of clinical apheresis.